Clinical trials: Schizophrenic Patients
Schizophrenia
A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients
The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).
- Trial name
- ETOS (NCT00999895)
- Where
- 43 sites in Greece
- Volunteers
- 574 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients in Integrated Care
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- CARE II (NCT00681629)
- Testing
- Quetiapine XR, Integrated Care Program (ICP)
- Where
- 8 sites in Germany
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained…
- Trial name
- NCT00392743
- Testing
- pet/spect scan
- Where
- 7 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Amisulpride in Schizophrenic Acute Phase Patients
To collect the safety and response of using Amisulpride in acute schizophrenic patients
- Trial name
- ASAP (NCT00436371)
- Testing
- Amisulpride
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Sanofi
Schizophrenia
In-Patient Study In Schizophrenic Patients
This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days.
- Trial name
- NCT00197093
- Testing
- SB773812
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Depression, Schizophrenia
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00034801
- Testing
- olanzapine, ziprasidone
- Where
- 30 sites in United States
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Schizophrenia
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
- Trial name
- NCT00036127
- Testing
- aripiprazole
- Where
- 16 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients Taking Part in Integrated Care Program
Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreni-form Disorder, Delusional Disorder
- Trial name
- CARE I (NCT00617214)
- Where
- 14 sites in Germany
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients
The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.
- Trial name
- NCT01819818
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 3,267 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
- Trial name
- ESPRIT (NCT00882518)
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended-Release (XR), Chlorpromazine
- Where
- 11 sites in China
- Volunteers
- 388 people
- Sponsor
- AstraZeneca
Schizophrenic Disorders
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine…
- Trial name
- NCT00088491
- Testing
- Intramuscular Olanzapine Depot, Oral Olanzapine
- Where
- 4 sites in Finland, Turkey (Türkiye)
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00159770
- Testing
- ziprasidone versus olanzapine , risperidone or quetiapine, Panss , CGI-C, UKU-SERS-Pa, Blood tests
- Where
- 43 sites in Denmark, Finland and 2 more
- Volunteers
- 290 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients.
- Trial name
- NCT00364429
- Testing
- [123]I-CNS 1261, Lorazepam, Risperidone
- Where
- Spain
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
The purpose of this study is to explore the pharmacokinetic profile and safety after biweekly (every 2-week) intramuscular (IM) injections (6 injections) of risperidone long acting injectable 25, 37.5, or 50 mg/dose in…
- Trial name
- NCT00653406
- Testing
- Risperidone long acting injectable
- Volunteers
- 29 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.
- Trial name
- NCT00191555
- Testing
- olanzapine, haloperidol
- Where
- 62 sites in France
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company